Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

ClinicalTrials.gov ID: NCT05263934

Public ClinicalTrials.gov record NCT05263934. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.

Study identification

NCT ID: NCT05263934
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 163 participants

Conditions and interventions

Conditions

Eosinophilic Granulomatosis With Polyangiitis

Interventions

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 14, 2022 (Actual)
Primary completion: Sep 29, 2026 (Estimated)
Completion: Oct 27, 2026 (Estimated)
Last update posted: Jul 8, 2026

2022 – 2026

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
GSK Investigational Site	Denver	Colorado	80206	—
GSK Investigational Site	Gainesville	Florida	32610	—
GSK Investigational Site	Rochester	Minnesota	55905	—
GSK Investigational Site	New York	New York	10021	—
GSK Investigational Site	Charlotte	North Carolina	28211	—
GSK Investigational Site	Pittsburgh	Pennsylvania	15261	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05263934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 8, 2026 · Synced Nov 9, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05263934 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →